Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products for autoimmune and inflammatory disorders, or immuno-inflammation, with high unmet medical need. Our initial product candidate, EQ001, or itolizumab, is a first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus and multiple sclerosis. We believe itolizumab may have broad therapeutic utility and our current pipeline is focused on developing itolizumab as a best-in-class treatment for multiple severe immuno-inflammatory disorders.
Data Provided by Refinitiv. Minimum 15 minutes delayed.